PEGylated haemoglobin and carbon monoxide

Drug Profile

PEGylated haemoglobin and carbon monoxide

Alternative Names: PEG haemoglobin; PEG haemoglobin carbon monoxide; PEG-bHb-CO; PEG-haemoglobin-CO; PEG-Hb; PEG-LEH; Pegylated carboxyhemoglobin bovine; Pegylated haemoglobin carbon monoxide; Polyethylene glycol modified bovine haemoglobin; Sanguinate

Latest Information Update: 10 Apr 2017

Price : $50

At a glance

  • Originator Enzon Pharmaceuticals; Rutgers
  • Developer Prolong Pharmaceuticals
  • Class Haemoglobins; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Oxygen carriers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Delayed graft function
  • Phase II Cerebral ischaemia; Sickle cell anaemia
  • Phase I Hypoxia; Kidney disorders
  • Clinical Phase Unknown Beta-thalassaemia

Most Recent Events

  • 01 Nov 2016 Prolong Pharmaceuticals completes a phase-II trial in Sickle cell anaemia (sickle cell disease associated leg ulcer) in Dominican Republic, Panama (IV) (NCT02600390)
  • 01 Oct 2016 Prolong Pharmaceuticals completes a phase II trial in Cerebral Ischaemia in USA (NCT02323685)
  • 01 Oct 2016 prolong Pharmaceuticals completes a phase II/III trial in Delayed graft function in USA (IV) (NCT02490202)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top